Regional Growth Fund Success Sees Malvern Instruments Stepping up UK Recruitment
News May 20, 2014
Malvern Instruments has been successful in securing £3 million support from the UK Government’s Regional Growth Fund (RGF) that will lead to the creation of 47 new jobs in the UK over the next five years.
Malvern develops, manufactures and markets materials and biophysical characterization systems. These are used to measure particle size, particle shape, zeta potential, protein charge, molecular weight, mass, size and conformation, rheology and for chemical identification.
This funding will support the research and development of new analytical instrumentation to serve the fast-growing nanomaterials and bioscience sectors, helping maximize Malvern’s export opportunities in these global markets. The company, which currently employs around 340 people in the UK and approaching 480 more in locations around the world, has already started recruiting to fill a variety of new posts.
“This major boost for Malvern Instruments enables us make significant investments in UK R&D, applications development and manufacturing engineering, to extend our links with UK universities and schools and to invest further in our apprentice programme,” said Managing Director Paul Walker. “It is good news not just for the company but also for the wider community in creating and securing employment opportunities and contributing further to the local economy.”
Malvern’s systems are used in research, development and manufacturing across many different industries. They provide information that is critical for developing new products, as well as for enhancing and maintaining product quality and improving process efficiency.
“The Bioscience and Nanomaterials markets require novel analytical techniques and the RGF funding will support our fundamental research in these areas, as well as enabling us to further develop the skills of new and existing employees,” continued Paul Walker. “Not only will we be looking to recruit additional R&D scientists, we are also creating new jobs in manufacturing engineering and operations to enable us to bring new products to market.”
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Study Debunks Fears of Increased Teen Suicide Risk From TamifluNews
Researchers from the University of Illinois at Chicago suggests that the drug oseltamivir - commonly known as Tamiflu - does not cause an increased risk of suicide in pediatric patients.READ MORE